The American Journal of Medicine
Volume 119, Issue 8 , Pages 684-692 , August 2006

Predischarge C-Reactive Protein and 1-year Outcome After Acute Coronary Syndromes

This paper was presented in part at the American Heart Association Scientific Sessions, on November 8, 2004.

  • Philippe Gabriel Steg, MD

      Affiliations

    • Department of Cardiology, Hôpital Bichat, Paris, France
    • Corresponding Author InformationRequests for reprints should be addressed to Philippe Gabriel Steg, MD, Hôpital Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    • ,
  • Philippe Ravaud, MD, PhD

      Affiliations

    • Department of Epidemiology, Biostatistics, and Clinical Research, Hôpital Bichat, Paris, France
    • ,
  • Alain Tedgui, PhD

      Affiliations

    • INSERM U-541, Hôpital Lariboisière, Paris, France
    • ,
  • Jacques Puel, MD

      Affiliations

    • Department of Cardiology, Hôpital Rangueil, Toulouse, France
    • ,
  • Dominique Moyse, MD

      Affiliations

    • Consultant in Biostatistics, Paris, France
    • ,
  • Emmanuelle Curaudeau, MS

      Affiliations

    • Department of Biostatistics, Bristol-Myers Squibb, Rueil-Malmaison, France
    • ,
  • Steven W. Quentzel, MD

      Affiliations

    • Cardiovascular Department, Bristol-Myers Squibb, Rueil-Malmaison, France.
    • ,
  • ELISCOR Investigators

References 

  1. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  2. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  3. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–466
  4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  5. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–424
  6. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:1139–1147
  7. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31:1460–1465
  8. Toss H, Lindahl B, Siegbahn A, Wallentin L FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. Circulation. 1997;96:4204–4210
  9. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999;100:1958–1963
  10. Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol. 1998;82:845–850
  11. Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano A. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol. 1997;80:1002–1006
  12. Montalescot G, Philippe F, Ankri A, et al. French Investigators of the ESSENCE Trial Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease (beneficial effects of enoxaparin). Circulation. 1998;98:294–299
  13. Kinjo K, Sato H, Ohnishi Y, et al. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol. 2003;91:931–935
  14. Harb TS, Zareba W, Moss AJ, et al. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol. 2002;89:216–221
  15. de Winter RJ, Heyde GS, Koch KT, et al. The prognostic value of pre-procedural 2*plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J. 2002;23:960–966
  16. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145–149
  17. Yip HK, Hang CL, Fang CY, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest. 2005;127:803–808
  18. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  19. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome (a GUSTO-IV substudy). J Am Coll Cardiol. 2003;41:916–924

 Supported by an unrestricted grant from Bristol-Myers Squibb, France. ELISCOR was supported by an unrestricted grant from Bristol-Myers Squibb, Rueil-Malmaison, France.The complete list of ELISCOR Investigators is in the Appendix.

PII: S0002-9343(06)00202-6

doi: 10.1016/j.amjmed.2006.02.018

The American Journal of Medicine
Volume 119, Issue 8 , Pages 684-692 , August 2006

Article Tools

* Image Usage & Resolution